GlaxoSmithkline Pharmaceuticals Limited reported audited consolidated and standalone earnings results for the fourth quarter and year ended March 31, 2018. For the quarter, the standalone company reported total income was INR 7,669.2 million compared to INR 7,988.2 million a year ago. Profit from operations exceptional items and tax were INR 1,636.1 million against INR 1,438.4 million for the same period of last year. Profit before tax was INR 1,636.1 million against INR 1,697.0 million for the same period of last year. Net profit was INR 1,055.5 million or INR 12.46 per basic and diluted share (not annualised) against INR 1,127.1 million or INR 13.31 per basic and diluted share for the same period of last year. For the year, the standalone company reported total income was INR 29,494.0 million compared to INR 30,665.2 million a year ago. Profit from operations exceptional items and tax were INR 5,237.8 million against INR 4,653.5 million for the same period of last year. Profit before tax was INR 5,415.8 million against INR 5,110.8 million for the same period of last year. Net profit was INR 3,519.8 million or INR 41.56 per basic and diluted share against INR 3,367.8 million or INR 39.76 per basic and diluted share for the same period of last year. For the year, the consolidated company reported total income was INR 29,501.9 million compared to INR 30,730.6 million a year ago. Profit from operations exceptional items and tax were INR 5,221.7 million against INR 4,654.6 million for the same period of last year. Profit before tax was INR 5,399.7 million against INR 5,111.9 million for the same period of last year. Net profit was INR 3,507.2 million or INR 41.41 per basic and diluted share against INR 3,368.2 million or INR 39.76 per basic and diluted share for the same period of last year.